Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bartalena, L. et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy — guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016).
Bartalena, L. et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 97, 4454–4463 (2012).
Sipkova, Z. et al. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease; a step-down approach. Clin. Endocrinol. https://doi.org/10.1111/cen.13834 (2018).
Perros, P., Crombie, A. L. & Kendall-Taylor, P. Natural history of thyroid associated ophthalmopathy. Clin. Endocrinol. 42, 45–50 (1995).
Goekoop-Ruiterman, Y. P. et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann. Rheum. Dis. 66, 1227–1232 (2007).
Kahaly, G. et al. Cyclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur. J. Clin. Invest. 16, 415–422 (1986).
Prummel, M. F. et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N. Engl. J. Med. 321, 1353–1359 (1989).
Kahaly, G. J. et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 6, 287–298 (2018).
Acknowledgements
This work was in part supported by Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan Italy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Salvi, M. Step-down steroid-sparing therapy in active thyroid eye disease. Nat Rev Endocrinol 14, 634–635 (2018). https://doi.org/10.1038/s41574-018-0099-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-018-0099-9